Literature DB >> 16091985

Prevalence of thyroid nodules and carcinomas in patients operated on for renal hyperparathyroidism: experience with 339 consecutive patients and review of the literature.

Daniel Seehofer1, Nada Rayes, Jochen Klupp, Natascha C Nüssler, Frank Ulrich, Klaus-Jürgen Graef, Ralph Schindler, Thomas Steinmüller, Ulrich Frei, Peter Neuhaus.   

Abstract

The association between renal hyperparathyroidism (HPT) and differentiated thyroid carcinoma is discussed. To determine the prevalence and potential risk factors, we performed a retrospective analysis of our patients (1998-2004) and compared the data with the data from other surgical and autopsy studies. At our hospital, a total of 347 parathyroidectomies in 339 patients with renal HPT were performed. Most patients underwent preoperative ultrasound investigation of the thyroid gland and, if indicate, thyroid scintigraphy. Intraoperatively, both thyroid lobes were mobilized and palpated. Detected thyroid nodules were adequately resected and investigated histologically. A systematic analysis of the international literature was performed using the PubMed/MEDLINE system to identify publications on the prevalence of papillary thyroid carcinoma (PTC) in patients with renal HPT and in the overall population. Altogether, 133 patients (39.2%) underwent simultaneous thyroid surgery. The initial operation was hemithyroidectomy in 55 (16.2%), Dunhill operation in 36 (10.6%), unilateral subtotal resection in 17 (5.0%), bilateral subtotal resection in 5 (1.5%), and enucleation of a thyroid nodule in 18 (5.3%). A PTC was found in 8 of 339 patients (2.4%) and a follicular thyroid carcinoma in 1. Among 311 patients with primary cervical operation, 6 (1.9%) had a papillary thyroid carcinoma. All papillary tumors were classified as pT1 with a diameter of 1 to 12 mm; three were bifocal, and only one patient had positive lymph nodes. None of the analyzed factors showed a significant correlation with the occurrence of thyroid carcinoma. Depending on the screening method, the prevalence of occult PTC in European autopsy studies ranged from 5% to 9% and was markedly higher in almost all studies than in the present one. The prevalence of PTC in the present study makes an etiologic association between renal HPT and PTC unlikely. The clinical significance of these tumors remains unclear because all incidental tumors were small. However, if easily and safely feasible, relevant thyroid nodules should be removed during parathyroid surgery.

Entities:  

Mesh:

Year:  2005        PMID: 16091985     DOI: 10.1007/s00268-005-7859-0

Source DB:  PubMed          Journal:  World J Surg        ISSN: 0364-2313            Impact factor:   3.352


  34 in total

1.  Secondary hyperparathyroidism and thyroid cancer.

Authors:  D A Linos; P N Ziroyannis
Journal:  Int Surg       Date:  1985 Jul-Sep

2.  Secondary hyperparathyroidism: evidence for an association with papillary thyroid cancer.

Authors:  M L Klyachkin; D A Sloan
Journal:  Am Surg       Date:  2001-05       Impact factor: 0.688

3.  Occult papillary thyroid carcinoma at autopsy in La Plata, Argentina.

Authors:  A Ottino; H M Pianzola; R H Castelletto
Journal:  Cancer       Date:  1989-07-15       Impact factor: 6.860

4.  Occult thyroid carcinoma. A study of 160 autopsy cases. The first report for the region of Epirus-Greece.

Authors:  Antigony Mitselou; Theodore Vougiouklakis; Dimitrios Peschos; Pavlos Dallas; Niki J Agnantis
Journal:  Anticancer Res       Date:  2002 Jan-Feb       Impact factor: 2.480

5.  Occult thyroid pathology in the young adult: an autopsy study of 138 patients without clinical thyroid disease.

Authors:  R A Komorowski; G A Hanson
Journal:  Hum Pathol       Date:  1988-06       Impact factor: 3.466

6.  Increased incidence of thyroid cancer in patients with primary hyperparathyroidism: a continuing dilemma.

Authors:  I J Fedorak; G Salti; N Fulton; C Schark; F H Straus; E L Kaplan
Journal:  Am Surg       Date:  1994-06       Impact factor: 0.688

7.  Latent carcinoma of thyroid in Israel: a study of 260 autopsies.

Authors:  A Siegal; M Modan
Journal:  Isr J Med Sci       Date:  1981-04

Review 8.  Controversies in papillary microcarcinoma of the thyroid.

Authors:  Monique Piersanti; Shereen Ezzat; Sylvia L Asa
Journal:  Endocr Pathol       Date:  2003       Impact factor: 3.943

9.  Increasing thyroid cancer incidence in Canada, 1970-1996: time trends and age-period-cohort effects.

Authors:  S Liu; R Semenciw; A M Ugnat; Y Mao
Journal:  Br J Cancer       Date:  2001-11-02       Impact factor: 7.640

10.  Thyroid cancer in uremic patients.

Authors:  T Hatada; K Okada; H Ishii; S Ichii; J Utsunomiya
Journal:  Tumori       Date:  1998 Jul-Aug
View more
  5 in total

Review 1.  Preoperative localization and minimally invasive management of primary hyperparathyroidism concomitant with thyroid disease.

Authors:  Yi-xiong Zheng; Shao-ming Xu; Ping Wang; Li Chen
Journal:  J Zhejiang Univ Sci B       Date:  2007-09       Impact factor: 3.066

2.  Incidental Finding of Papillary Thyroid Carcinoma in the Patients with Primary Hyperparathyroidism.

Authors:  Pinar Yazici; Mehmet Mihmanli; Emre Bozdag; Nurcihan Aygun; Mehmet Uludag
Journal:  Eurasian J Med       Date:  2015-10

Review 3.  The surgical treatment of bilateral benign nodular goiter: balancing invasiveness with complications.

Authors:  Nada Rayes; Daniel Seehofer; Peter Neuhaus
Journal:  Dtsch Arztebl Int       Date:  2014-03-07       Impact factor: 5.594

4.  Long-term therapeutic outcomes of papillary thyroid carcinoma with concomitant hyperparathyroidism: A single center case-control study.

Authors:  Chih-Yiu Tsai; Szu-Tah Chen; Chuen Hsueh; Yann-Sheng Lin; Jen-Der Lin
Journal:  Biomed J       Date:  2020-02-27       Impact factor: 4.910

5.  Increased incidence of malignancy in patients with primary hyperparathyroidism

Authors:  Melia Karaköse; Muhammet Kocabaş; Mustafa Can; Hatice Çalışkan Burgucu; İlker Çordan; Mustafa Kulaksızoğlu; Feridun Karakurt
Journal:  Turk J Med Sci       Date:  2021-08-30       Impact factor: 0.973

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.